Publications

Preclinical
PEGS
November 5, 2024
Trispecific T Cell Engagers Incorporating Conditional CD28 Co-stimulation (TriTCE Co-stim) to Improve Treatment Responses in Oncology
Nina Weisser
Preclinical
PEGS
November 5, 2024
Azymetric Fc-based Therapeutic Modalities Enabling Tumor-Restricted Immune Cell Activation and Engagement
Thomas Spreter von Kreudenstein
Preclinical
AACR-EORTC-NCI
October 25, 2024
ZW220, a NaPi2b-directed TOPO1i ADC, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in NHPs
Andrea Hernández Rojas
Preclinical
AACR-EORTC-NCI
October 24, 2024
Beyond ADC Target Expression: Understanding ADC Properties and Pharmacology
Raffaele Colombo
Preclinical
AACR, Cancer Discovery
October 23, 2024
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo et al.
Preclinical
AACR-EORTC-NCI
October 23, 2024
ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload, demonstrates compelling preclinical activity in hepatocellular carcinoma models
Madera et al.
Preclinical
World Bispecific Summit
September 4, 2024
Leveraging Azymetric to Optimally Format T-Cell Engagers and Bispecific ADCs
Preclinical
ACS
August 21, 2024
Design and selection of the novel camptothecin analog ZD06519: A payload optimized for antibody-drug conjugates
Brant et al.
Preclinical
Immuno-Oncology Summit
August 7, 2024
Building Differentiated & Next Generation T Cell Engagers to Improve Responses in Difficult-to-Treat Tumors.
Nicole Afacan
Preclinical
ACS
June 23, 2024
Development of a Novel TOPO1i ADC Platform: From Concept to Pipeline Application
Mark Petersen
Preclinical
PEGS
May 16, 2024
Screening Novel Format Antibodies to Design Bispecific ADCs that Address Target Heterogeneity
Dunja Urosev
Preclinical
PEGS
May 16, 2024
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve T cell function and anti-tumor responses in hard-to-treat cancers
Newhook et al.